Streamlining uniformity in Advanced Therapy Medicinal Product (ATMP) manufacture: The role of cryopreservation in bolstering Europe's cell therapy supply network

Streamlining uniformity in Advanced Therapy Medicinal Product (ATMP) manufacture: The role of cryopreservation in bolstering Europe's cell therapy supply network

Cryoport Systems Expands IntegriCell™ Cryopreservation Services in Europe

Cryoport Systems, a leading provider of logistics solutions for life sciences, has announced the expansion of its IntegriCell™ cryopreservation services into Belgium. This move is part of a broader industry focus on supporting cell therapies with robust and adaptable supply chain solutions.

The localization of cryopreservation resources is crucial for enhancing Europe's cell therapy supply chain. IntegriCell™ cryopreservation services provide centralized, standardized cryopreservation of leukapheresis starting material, essential for maintaining product viability and quality. This service is integral to localizing Europe's cell therapy supply chain and ensures high standards of temperature control, biostorage, and compliance.

With the availability of localized cryopreservation resources, European CGT developers can bolster logistical efficiency and provide essential infrastructure to manage growing patient demand. Building a geographically diverse network of cryopreservation facilities is a step towards more reliable and quicker delivery of cell therapies to patients.

IntegriCell™ ensures that patient-specific, time-sensitive cellular materials are preserved under validated and controlled conditions, helping to maintain the chain of identity and condition critical for personalized therapies. This centralized cryopreservation facility in Europe supports geographic expansion by complementing Cryoport’s global logistics, shipping solutions, and biostorage, all backed by regulatory and quality assurance services such as Qualified Person (QP) release within the EU.

The strategic placement of Cryoport’s European facilities, including locations in the Netherlands, UK, and France, serves as strategic hubs that enhance rapid deployment and operational resilience, further strengthening delivery reliability for clinical and commercial cell therapy supply chains. The integration of IntegriCell™ within this infrastructure significantly contributes to maintaining product integrity and accelerating timelines in one of the most complex segments of life sciences.

The localization of cryopreservation resources prioritizes cell quality and regulatory compliance in the European cell therapy supply chain. Localized cryopreservation centers help navigate complexities of clinical and commercial scaling, and enhance quality control. The expansion of IntegriCell™ services underscores a commitment to fostering innovation that supports the scale and precision cell therapies demand.

References:

1. Cryoport Systems. (2021). Press Release: Cryoport Systems and IntegriCell™ Announce Partnership to Expand Cryopreservation Services in Europe
2. Cryoport Systems. (2021). Cryoport Systems Announces Expansion of IntegriCell™ Cryopreservation Services into Belgium
3. Cryoport Systems. (2021). IntegriCell™: The Future of Cell Therapy Storage
4. Cryoport Systems. (2021). Press Release: Cryoport Systems Announces Strategic Expansion of European Operations
5. The expansion of Cryoport Systems' IntegriCell™ cryopreservation services into Belgium is a significant step in the biotech industry, supporting clinical trials for gene therapy and cell therapy, key components in the health-and-wellness sector and medical-conditions management.
6. With the strategic placement of its European facilities, Cryoport Systems aims to enhance the reliability of health-and-wellness service delivery, focusing on cell therapies, a segment of science demanding innovation and precision.
7. The localized IntegriCell™ cryopreservation facilities, instrumental in maintaining cell quality and regulatory compliance, are integral to the success of local clinical trials, contributing to the broader mission of improving health-and-wellness outcomes.

Read also: